10. Human papillomavirus
(HPV人類乳突病毒)
J Natl Cancer Inst. 2011 Mar 2;103(5):368-83
Small, non-enveloped, dsDNA viruses
Tightly restricted host range – only
keratinocytes of the skin or mucous
membranes.
11. 1. Woodman et al. Nature Reviews Cancer 7, 11–22 (January 2007) | doi:10.1038/nrc2050 2. Stanley M, Lowy DR, Frazer I. Vaccine.
2006;24(suppl 1):S16–S22
HPV Infection and disease
progression
12. 12
HPV infection and Cervical cancer
~1 Year
2–5
Years
4–5
Years
子宮頸
侵襲癌
持 續 性 感 染
暫 時 性 感 染
癌前病變
第一級
CIN 1
Over 2
Years
9–15
Years
HPV 感 染
癌前病變
第二,三級
CIN 2/3
正常子宮頸
• 約80~90%的HPV感染會在一年內痊癒
• 但若HPV造成持續性的感染,則可能引發子宮頸癌前病變,甚至癌症
18. Gardasil is a registered trade mark of Merck & Co., Inc
Gardasil. European Summary of Product Characteristics, 2012. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000703/WC500021142.pdf (accessed May 2013); Cervarix. European Summary of Product Characteristics, 2012.
Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000721/WC500024632.pdf (accessed
May 2013); HPV, human papillomavirus; VLP, virus-like particle
荷商葛蘭素史克
美商默沙東藥廠
47. Long-term efficacy of CERVARIX in Finland
• Phase III HPV vaccination trial populations enrolled in cancer
registry based long-term follow-up
PATRICIA
Finland
HPV 16/18
2,469
HAV
2,399
Unvaccinated
cohort
48. • 一樣給予 3-dose Cervarix,10-14 y/o 青少年的抗體反應為
15-25 y/o 族群的二倍
青少女的免疫生成性優於成人
Pedersen, Journal of Adolesent Health, 2007, Jun;40(6):564-71
EMA. Cervarix® . European Summary of Product Characteristics 2013
HPV 18
15-25 years
10-14 years
M48M36M24M7
Plateau
phase
Natural
infection
49. Antibody
2-dose in 9-
14y
(N)
2-dose in
9-14y
(%)
3-dose in
15-25y
(N)
3-dose in
15-25y
(%)
Difference
(3 dose)-(2 dose)
%
95% CI
LL UL
HPV-16 492 100 380 100
HPV(0,1,6) -
HPV(0,6)
0.00 -1.00 0.78
HPV-18 497 100 412 100
HPV(0,1,6) -
HPV(0,6)
0.00 -0.92 0.77
HPV(0,6) = Females aged 9-14 years who received 2 doses of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine at Day 0 and Month 6
HPV(0,1,6) = Females aged 15-25 years who received 3 doses of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine at Day 0, Month 1 and Month 6
N = number of subjects with available results
% = percentage of subjects with HPV 16.VLP Ab.IgG concentration ≥ 8 EU/ml
95% CI = 95% Standardized asymptotic confidence interval; LL = lower limit, UL = upper limit
The upper limit of 95% Confidence Interval (CI) for the difference (Seroconv 3d
minus Seroconv 2d) is below 5%.
Data extracted from CSR 070
9-14歲使用兩劑施打時程的免疫生成性與三劑施打時程
相當 (M7, ELISA)
3-dose in 15-
25 y (N)
3-dose in
15-25 y
(GMTs)
2-dose in 9-
14 y (N)
2-dose in 9-
14 y (GMTs)
GMT
ratio
3d/2d
95% CI
LL UL
HPV-16 352 10234.5 488 9400.1 1.09 0.97 1.22
HPV-18 382 5002.6 493 5909.1 0.85 0.76 0.95
The upper limit of the 95% CI for the GMT ratio (GMT 3-Dose/GMT 2-dose) is below 2
血清陽轉率
抗體濃度
50. HPV-16 HPV-18
兩劑施打與三劑施打時程的免疫反應
M60; ELISA
• 兩劑施打(9-14y)的抗體反應與三劑施打(15-25y)相當
• GMTs above plateau level seen in subjects with sustained protection (HPV-001/007)
• GMTs above levels elicited after natural infection (HPV-008)
Human Vaccines & Immunotherapeutics 10:5, 1155–1165; May 2014
Romanowski, et al Abstract, ESPID 2014, Dublin, Ireland
3D M0,1,6 15-25 years 2D M0,6 9-14 years
HPV-16 Antibodies HPV-18 Antibodies
Natural infection 22.6 EU/mlNatural infection 29.8 EU/ml
Plateau 397.8 EU/ml
Plateau 297.3 EU/ml
60 60
51. 兩劑施打(M0,12)抗體反應與M0,6 或M0,1,6相當
• Antibody titres 1 month after last dose
• The immunological non-inferiority of the 2D (M0,12) schedule compared to
both the 3D(M0,1,6) and 2D(M0,6) schedules
Anti-HPV16 antibody Anti-HPV18 antibody
initially seronegative participants, ATP cohort
3D 2D
0,6
2D
0,12 3D 2D
0,6
2D
0,12
52.
53. HPV抗體有無無法確定過去是否被HPV感染
588 women Seroconversion
followed 24 months 54~69%
Human papillomavirus (HPV) seroprevalence and determinants of seropositivity were
assessed in a 10049-woman. J Infect Dis. 2000, 181: 1911−1919. Carter JJ, et al
Median seroconversion = 9 months
54. Similar Attack Rates In Seronegative & Seropositive Women
Attackrates(%)*
自然感染產生之抗體無法提供足夠的保護力
*in HPV DNA negative women being either seronegative or seropositive at HPV-008 study start in the control group
Seronegative
Data on file Study 580299/008 (HPV-008) GSKBio_WWWMA_DoF12_2008
Seropositive
Incident infection 6-months persistent infection
自然感染不產生抗體或只能產生少量抗體